M. Isabel Chiu
Corporate Officer/Principal en C4 THERAPEUTICS, INC. .
Perfil
M.
Isabel Chiu is a professional with experience in the biotech and pharmaceutical industries.
She is currently the SVP-Strategic Alliances & Business Development at C4 Therapeutics, Inc. Her former positions include Director-Target Discovery at GPC Biotech, Inc., Vice President-Translational & Clinical Sciences at Enumeral Biomedical Holdings, Inc., and Vice President-Translational Research at AVEO Pharmaceuticals, Inc. Chiu holds a doctorate degree from the Massachusetts Institute of Technology and an undergraduate degree from Brandeis University.
Cargos activos de M. Isabel Chiu
| Empresas | Cargo | Inicio |
|---|---|---|
| C4 THERAPEUTICS, INC. | Corporate Officer/Principal | 01/03/2016 |
Antiguos cargos conocidos de M. Isabel Chiu.
| Empresas | Cargo | Fin |
|---|---|---|
| ENUMERAL BIOMEDICAL HOLDINGS INC | Corporate Officer/Principal | - |
| AVEO PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
GPC Biotech, Inc.
 GPC Biotech, Inc. Drugstore ChainsRetail Trade GPC Biotech, Inc. discovers and develops anticancer drugs through discovery technologies and development approaches. It is a mechanism-based drug discovery and development company focused on treatments for cancer and fungal infections. The company is a wholly owned subsidiary of GPC Biotech AG. GPC Biotech was founded in 1992 and is located in Waltham, MA. | Corporate Officer/Principal | - |
Formación de M. Isabel Chiu.
| Brandeis University | Undergraduate Degree |
| Massachusetts Institute of Technology | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| C4 THERAPEUTICS, INC. | Health Technology |
| Empresas privadas | 3 |
|---|---|
GPC Biotech, Inc.
GPC Biotech, Inc. Drugstore ChainsRetail Trade GPC Biotech, Inc. discovers and develops anticancer drugs through discovery technologies and development approaches. It is a mechanism-based drug discovery and development company focused on treatments for cancer and fungal infections. The company is a wholly owned subsidiary of GPC Biotech AG. GPC Biotech was founded in 1992 and is located in Waltham, MA. | Retail Trade |
Enumeral Biomedical Holdings, Inc.
 Enumeral Biomedical Holdings, Inc. BiotechnologyHealth Technology Enumeral Biomedical Holdings, Inc. is a biopharmaceutical company, which engages in the business of discovering and developing novel antibody immunotherapies for the treatment of cancer and other diseases. It also focuses on the development of a pipeline of next generation monoclonal antibody drugs targeting established and novel immuno-modulatory receptors. The company was founded by Barry C. Buckland, John J. Rydzewski, and Arthur H. Tinkelenberg on December 11, 2009 and is headquartered in Arlington, MA. | Health Technology |
AVEO Pharmaceuticals, Inc.
 AVEO Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA. | Health Technology |
- Bolsa de valores
- Insiders
- M. Isabel Chiu
